PYC Therapeutics (ASX:PYC) said it is preparing for upcoming human safety and efficacy read-outs across its polycystic kidney disease (PKD), lead blinding eye disease (RP11), second blinding eye disease (ADOA), and neurodevelopmental disorder (PMS) drug development programs, according to a Monday filing with the Australian bourse.

Data for RP11 is expected in the fiscal year, while data for PKD and ADOA is expected the next year, the filing said. Data for PMS is expected in fiscal 2027.

The biotechnology company's shares jumped almost 3% in recent Monday trade.